{
    "nct_id": "NCT04294225",
    "official_title": "Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer",
    "inclusion_criteria": "* REGISTRATION-INCLUSION CRITERIA\n* Disease characteristics:\n\n  * Histological confirmation of invasive breast carcinoma\n  * Stage I-III breast cancer\n  * Estrogen receptor (ER) positive disease according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as ER >= 1% positive nuclear staining\n* Completion of all planned cancer treatments prior to registration:\n\n  * Surgical resection of breast and nodal surgery; (NOTE: Reconstructive surgery does not have to be completed)\n  * Adjuvant radiation therapy, if needed\n  * Neoadjuvant and/or adjuvant chemotherapy, if needed\n* Post-menopausal defined as\n\n  * Age >= 60 and amenorrhea > 12 consecutive months OR\n  * Previous bilateral oophorectomy OR\n  * Age < 60 and amenorrhea > 12 consecutive months and documented follicle stimulating hormone (FSH) level within post-menopausal range according to institutional standard\n\n    * NOTE: Patients who did not meet these criteria at time of diagnosis and received pre-operative (neoadjuvant) or post-operative (adjuvant) chemotherapy will not be allowed to participate\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to registration)\n* Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)\n* Platelet count >= 70,000/mm^3 (obtained =< 14 days prior to registration)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 14 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)\n* Ability to swallow oral medication\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n* RE-REGISTRATION-INCLUSION CRITERIA\n* Confirmation that baseline blood sample was drawn and submitted\n* Blood estrogen levels after cycle 1 anastrozole (ANA1) must meet the following criteria:\n\n  * E1 >= 1.3 pg/ml, AND\n  * E2 >= 0.5 pg/ml\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* REGISTRATION-EXCLUSION CRITERIA\n* Pre-menopausal women receiving ovarian function suppression (goserelin, leuprolide, etc.)\n* Stage IV (metastatic) breast cancer\n* HER2 positive breast cancer as defined by\n\n  * HER2 immunohistochemistry (IHC) >= 3+\n  * HER2/CEP17 >= 2.0\n  * HER2/CEP17 < 2.0 and average HER2 copy number of >= 6.0 signals/cell\n* Prior endocrine therapy for this breast cancer. Exceptions:\n\n  * Pre-operative aromatase therapy (anastrozole, letrozole, or exemestane) and last treatment was >= 4 weeks prior to registration OR\n  * Pre-operative tamoxifen therapy and last treatment was >= 12 weeks prior to registration\n* Currently receiving any of the following cancer-directed therapies:\n\n  * Radiation therapy\n  * Systemic therapy such as chemotherapy (standard or investigational)\n* Bisphosphonate therapy started < 4 weeks prior to registration\n\n  * NOTE: If patient is currently on bisphosphonate therapy she must be on stable dose for >= 4 weeks prior to registration. Patients not currently taking bisphosphonates will be allowed to start bisphosphonate therapy after completion of anastrozole (1 mg and 10 mg daily [if given]). Information regarding bisphosphonate therapy will be collected\n* Current use of systemic or topical exogenous estrogen or progesterone (menopausal hormone replacement therapy [HRT])\n* Prior ovarian function suppression (leuprolide, goserelin, etc.)\n* Inability to provide informed consent\n* History of contralateral ductal carcinoma in situ (DCIS) or invasive breast cancer\n\n  * NOTE: Exception allowed if\n\n    * Patient did not receive adjuvant endocrine therapy OR\n    * Patient received adjuvant endocrine therapy but has been off treatment for at least 6 months prior to registration\n* Concurrent active malignancy or history of malignancy =< 3 years prior to registration\n\n  * NOTE: Exceptions allowed for successfully treated cervical carcinoma in situ, lobular carcinoma in situ of the breast, papillary thyroid cancer, or non-melanoma skin cancer\n* Prior prevention therapy with an aromatase inhibitor or a selective estrogen receptor modulator (SERM). Exception: Therapy with a SERM (tamoxifen or raloxifene) is allowed if patient has been off treatment for >= 6 months prior to registration",
    "miscellaneous_criteria": ""
}